Erythema Annulare Centrifugum in the Era of Triple Therapy with Boceprevir plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection
Restricted accessLetterFirst published online May, 2015
Erythema Annulare Centrifugum in the Era of Triple Therapy with Boceprevir plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection
FeretB.Boceprevir: a new oral protease inhibitor for the treatment of chronic hepatitis C.Formulary.2011; 46: 352–366.
2.
HézodeC. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice.Liver Int.2012; 32 (suppl 1): 32–38.
3.
NayakSU, ShenoiSD, PrabhuSM.Erythema annulare centrifugum: deep variant with vasculitis like histopathology.Indian J Dermatol.2013; 58: 329.
4.
NaccaratoM, YoongD, SolomonR, OstrowskiM.Erythema annulare centrifugum-like eruption associated with pegylated interferon treatment for hepatitis C.Dermatol Reports.2013; 5(1): e1.
5.
GönülM, Külcü ÇakmakS, OzcanN, Deniz OǧuzI, OzhamamE.Erythema annulare centrifugum due to pegylated interferon-α-2a plus ribavirin combination therapy in a patient with chronic hepatitis C virus infection.J Cutan Med Surg.2014; 18: 65–68.
